Developing a vaccine to prevent HIV infection at mucosal sites
Intrarectal Immunization for a Barrier to Mucosal HIV Infection
This study is testing a new vaccine designed to help your body fight HIV right at the spots where the virus usually enters, with the hope of giving you better protection against getting infected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11077331 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine that targets the mucosal surfaces where HIV typically enters the body. By stimulating the immune system at these entry points, the goal is to enhance the body's ability to block or contain the virus before it can spread. The approach involves delivering viral antigens to mucosal tissues over time, which may help maintain a heightened immune response. This innovative strategy aims to provide both immediate and long-term protection against HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV exposure, particularly those with mucosal vulnerabilities.
Not a fit: Patients who are already living with HIV or those who do not have risk factors for HIV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the risk of HIV infection.
How similar studies have performed: While there have been many attempts at HIV vaccines, this approach is novel and aims to address specific barriers that previous vaccines have not successfully tackled.
Where this research is happening
San Antonio, United States
- Texas Biomedical Research Institute — San Antonio, United States (Active)
Researchers
- Principal investigator: Gauduin, Marie-Claire Elisabeth — Texas Biomedical Research Institute
- Study coordinator: Gauduin, Marie-Claire Elisabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.